BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang Q, Li X. Molecular Network Basis of Invasive Pituitary Adenoma: A Review. Front Endocrinol (Lausanne) 2019;10:7. [PMID: 30733705 DOI: 10.3389/fendo.2019.00007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 García-Martínez A, López-Muñoz B, Fajardo C, Cámara R, Lamas C, Silva-Ortega S, Aranda I, Picó A. Increased E2F1 mRNA and miR-17-5p Expression Is Correlated to Invasiveness and Proliferation of Pituitary Neuroendocrine Tumours. Diagnostics (Basel) 2020;10:E227. [PMID: 32316225 DOI: 10.3390/diagnostics10040227] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
2 Zhang C, Qian Y, Qiao Y, Li Y, Wang W, Li J, Deng X. Analysis of whole genome-wide microRNA transcriptome profiling in invasive pituitary adenomas and non-invasive pituitary adenomas. Chin Neurosurg J 2019;5:27. [PMID: 32922926 DOI: 10.1186/s41016-019-0177-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 He C, Yang J, Ding J, Li S, Wu H, Zhou F, Teng L, Yang J. MiR-448 targets BLC2 and inhibits the growth of pituitary adenoma cells. Biochem Cell Biol 2020;98:511-7. [PMID: 32648768 DOI: 10.1139/bcb-2019-0336] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Wang L, Zhang J. Long intergenic ncRNA 00473 improves the invasion of trophoblastic cells via miR-16-5p. Pregnancy Hypertens 2021;23:174-84. [PMID: 33422740 DOI: 10.1016/j.preghy.2020.12.003] [Reference Citation Analysis]
5 Long R, Liu Z, Li J, Yu H. COL6A6 interacted with P4HA3 to suppress the growth and metastasis of pituitary adenoma via blocking PI3K-Akt pathway. Aging (Albany NY) 2019;11:8845-59. [PMID: 31627190 DOI: 10.18632/aging.102300] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
6 Gossing W, Frohme M, Radke L. Biomarkers for Liquid Biopsies of Pituitary Neuroendocrine Tumors. Biomedicines 2020;8:E148. [PMID: 32498309 DOI: 10.3390/biomedicines8060148] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Kim YH, Kim JH. Transcriptome Analysis Identifies an Attenuated Local Immune Response in Invasive Nonfunctioning Pituitary Adenomas. Endocrinol Metab (Seoul) 2019;34:314-22. [PMID: 31565884 DOI: 10.3803/EnM.2019.34.3.314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Perepechaeva ML, Grishanova AY. The Role of Aryl Hydrocarbon Receptor (AhR) in Brain Tumors. Int J Mol Sci 2020;21:E2863. [PMID: 32325928 DOI: 10.3390/ijms21082863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Tang H, Cheng Y, Huang J, Li J, Zhang B, Wu ZB. Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists. Front Endocrinol (Lausanne) 2021;12:616339. [PMID: 33776913 DOI: 10.3389/fendo.2021.616339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Peculis R, Niedra H, Rovite V. Large Scale Molecular Studies of Pituitary Neuroendocrine Tumors: Novel Markers, Mechanisms and Translational Perspectives. Cancers (Basel) 2021;13:1395. [PMID: 33808624 DOI: 10.3390/cancers13061395] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Šošić-Jurjević B, Ajdžanović V, Miljić D, Trifunović S, Filipović B, Stanković S, Bolevich S, Jakovljević V, Milošević V. Pituitary Hyperplasia, Hormonal Changes and Prolactinoma Development in Males Exposed to Estrogens-An Insight From Translational Studies. Int J Mol Sci 2020;21:E2024. [PMID: 32188093 DOI: 10.3390/ijms21062024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Liu D, Li J, Li N, Lu M, Wen S, Zhan X. Integration of quantitative phosphoproteomics and transcriptomics revealed phosphorylation-mediated molecular events as useful tools for a potential patient stratification and personalized treatment of human nonfunctional pituitary adenomas. EPMA J 2020;11:419-67. [PMID: 32849927 DOI: 10.1007/s13167-020-00215-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
13 Wang Y, Zhao J, Zhang C, Wang P, Huang C, Peng H. MiR-219a-2-3p suppresses cell proliferation and promotes apoptosis by targeting MDM2/p53 in pituitary adenomas cells. Biosci Biotechnol Biochem 2020;84:911-8. [PMID: 31959058 DOI: 10.1080/09168451.2020.1715780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Serioli S, Doglietto F, Fiorindi A, Biroli A, Mattavelli D, Buffoli B, Ferrari M, Cornali C, Rodella L, Maroldi R, Gasparotti R, Nicolai P, Fontanella MM, Poliani PL. Pituitary Adenomas and Invasiveness from Anatomo-Surgical, Radiological, and Histological Perspectives: A Systematic Literature Review. Cancers (Basel) 2019;11:E1936. [PMID: 31817110 DOI: 10.3390/cancers11121936] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
15 Dai C, Liang S, Sun B, Li Y, Kang J. Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review. Front Oncol 2021;11:773905. [PMID: 34869016 DOI: 10.3389/fonc.2021.773905] [Reference Citation Analysis]